

INDEX

- Acne
 - Pathogenesis, 163ff
 - treatment by DPIV inhibitors, 164ff
- ACPH, *see* acylaminoacyl peptide hydrolase
- Acylaminoacyl peptide hydrolase, 34, 38ff, 73
- ADA, *see* adenosine deaminase
- Adenosine deaminase, 51f
- Alanyl aminopeptidase (APN, CD13)
 - expression in T cells, 143ff, 182ff
 - function, 181ff, 223ff
 - inhibitors, 181ff, 223ff
- Aminopeptidase M, 19ff
- Aminopeptidase P, 19ff
- AMPK, *see* AMP-activated protein kinase
- AMP-activated protein kinase, 126
- Animal models
 - CLO New Zealand White rabbits, 75
 - DSS-induced colitis (mouse), 143ff, 155ff
 - experimental autoimmune encephalomyelitis (EAE, mouse), 177ff
 - Fischer344 rat, 5, 48
 - injured carotide artery (rat), 137
 - Lewis (LEW) × Brown Norway (BN) F₁ hybrids (LBNF₁), 232
 - Lewis (RT1[']), 232
 - Obese diabetic rat, 126
 - Streptozotocin (STZ) diabetes, 126
 - Swiss mice, 75
 - VDF Zucker rat, 123, 125
 - Wistar rats, 75
- APM, *see* aminopeptidase M
- APP, *see* aminopeptidase P
- Arthritis
 - psoriatic, 169f
 - rheumatoid, 169f
- Attractin
 - characteristics, 55ff, 109ff
 - expression on blood cells, 87ff
 - inhibition by Lys[Z(NO₂)]-thiazolidide (I49), 87ff
 - mRNA detection, 89f
 - tissue expression, 109ff
- Blood mononuclear cells, 87ff
- BNP-32, *see* brain natriuretic peptide
- Brain natriuretic peptide, 4f
- Chemokines, 9ff, 177ff, 200f
- Cytokines
 - inflammatory, 166ff, 190f
 - immunosuppressive, 87, 143ff, 166ff, 177ff, 190f
- DASH, *see* DPIV activity- and/or structure-homologues
- Diabetes mellitus type 2
 - DPIV inhibitors, 119ff
 - GLP-1, 122ff
 - GIP, 123ff
- Dipeptidyl peptidase 8
 - active site, 35f
 - adhesion, 63ff, 70
 - apoptosis, 63ff, 70
 - characteristics, 63, 93ff
 - enzymatic activity, 93ff
 - enzyme kinetics, 95
 - expression, recombinant, 93ff
 - inhibitor sensitivity, 95f
 - migration, 66
 - purification, 95ff
 - structure, 30, 35, 37
 - structural model, 33ff
 - substrates, 95ff
 - tissue expression, 63ff, 93ff
 - tumor, 55ff
 - wound healing, 215
- Dipeptidyl peptidase 9
 - active site, 35f
 - adhesion, 63ff, 70
 - apoptosis, 70
 - cancer, 55ff
 - characteristics, 63
 - structure, 45ff, 63ff
 - substrates, 109ff, 119ff
 - tissue expression, 109ff, 119ff

- Dipeptidyl peptidase (*cont.*)
 tumor, 55ff
 wound healing, 67ff
- Dipeptidyl peptidase II
 characteristics, 13f
 inhibition kinetics, 87ff
 inhibitors, 73ff
 tissue expression, 109ff
- Dipeptidyl peptidase IV
 active site, 51
 activity- and/or structure-homologues, 55ff, 87,
 109ff, 169ff
 ADA binding site, 55ff
 adhesion, 55ff, 213ff
 angiogenesis, 136f, 213f
 atherosclerosis, 137
 cancer, colon, 56, 200
 cancer, Ewing's sarcoma, 223ff
 cancer, lung, 56, 199
 cancer, ovarian, 56, 201f
 cancer, prostate, 56, 200f
 cancer, skin (melanoma), 56, 198f
 cell proliferation, 136ff, 165ff
 characteristics, 187ff
 co-localization with MMPs, 207ff
 crystallisation, 28f, 50
 diabetes, 125ff
 deficient Fischer344 rat, 48f
 enzyme kinetics, 56
 expression, recombinant, 28ff, 55ff
 expression in rheumatoid arthritis, 169ff
 graft function, 231ff
 incretin cleavage, 119ff
 inhibitors, 5ff, 19ff, 55ff, 87ff, 109ff, 119ff,
 135ff, 143ff, 155ff, 163ff, 177ff, 187ff, 223ff,
 231ff
 knock-out mouse, 4ff, 157ff
 matrix degradation, 207ff, 213ff
 migration, 207ff, 213ff
 substrates, 2ff
 specificity constant, 2, 24
 structural model, 37, 65
 structure, 33f, 45ff, 50
 therapy, acne, 163ff
 therapy, EAE, 177ff
 therapy, colitis, 143ff, 155ff
 therapy, diabetes, 119ff
 transplantation, 231ff
- Diprotin A and -B, 5, 50
- DP4, *see* dipeptidyl peptidase IV
- DP8, *see* dipeptidyl peptidase 8
- DP9, *see* dipeptidyl peptidase 9
- DPII, *see* dipeptidyl peptidase II (DPP II)
- DPIV, *see* dipeptidyl peptidase IV
- DPL1, 33ff, 45ff
- DPL2, 45ff
- EAE, *see* experimental autoimmune encephalitis
- Endomorphin, 6
- Eotaxin, 10f
- ESFT, *see* Ewing's sarcoma family of tumors
- Ewing's sarcoma family of tumors
 cell lines, 223ff
 effect of DPIV inhibition, 223f
 expression of DASH, 224f
 NPY, 224f
 regulation of growth by DPIV, 223f
- Experimental autoimmune encephalitis
 pathogenesis, 179f
 treatment by DPIV inhibitors, 177ff
- FAP, *see* fibroblast activation protein
- fibroblast activation protein
 adhesion, 209ff, 213ff
 breast cancer, 203
 expression, 197ff, 213f
 matrix degradation, 209ff
 melanoma, 198f, 202f
 migration, 216ff
 overexpression, 28f, 57f, 214ff
 structure, 49f
 substrates, 12f
 vesicular localization, 207ff
 wound healing, 215f
- Fischer344 rat, 5, 48
- Gastric inhibitory peptide, 7f, 119ff
- Gastrin-releasing peptide, 9
- GIP, *see* Gastric inhibitory peptide
- GLP, *see* Glucagon-like peptide
- Glucagon-like peptide, 7f, 35, 155ff, 196f
- GRP, *see* Gastrin-releasing peptide
- Hemorphin, 3, 4, 6
- IBD, *see* Inflammatory bowel disease
- Incretins
 degradation, 119ff
 signal transduction, 121f
 therapy of diabetes, 119ff
- Inflammatory bowel disease
 treatment by DPIV inhibitors, 143ff, 155ff
- Inhibitors
 actinonin, 182f
 diprotin A, -B, 5, 50
 isoleucyl-cyano-pyrrolidine, 158ff
 isoleucyl-thiazolidide, 158ff
 Lys[Z(NO₂)]-pyrrolidide (I40), 87, 165f, 180ff
 Lys[Z(NO₂)]-thiazolidide (I49), 48, 87, 165f,
 180ff
 P32/98, 223ff
 pyrrolidide, 19ff
 thiazolidide, 19ff

- UAMC00039, 73ff
- Val-boro-Pro, 48
- valine-pyrrolidide, 7f
- interferon-inducible T cell α chemoattractant, 11f
- ITAC, *see* interferon-inducible T cell α chemoattractant
- Keratinocyte, 163f
- Knock-out mice
 - DPIV, 4, 6ff, 157f, 189ff
 - FAP, 46, 48f
 - incretin receptor (DIRKO), 122
- LAP, *see* leucine aminopeptidase
- Leucine aminopeptidase, 19f
- Multiple sclerosis, 177ff
- N-(4-chlorobenzyl)-4-oxo-4-(1-piperidiny)-1,3-(S)-butane-diamine, *see* UAMC00039
- Neuropeptide Y, 4f, 135ff, 223ff
- NP Y, *see* neuropeptide Y
- NP Y receptor, 4, 59, 135ff, 228
- Opioid peptides, 6f
- PACAP, *see* pituitary adenylate cyclase activating polypeptide
- PEP, *see* prolyl endopeptidase
- Peptide YY, 6
- Pituitary adenylate cyclase activating polypeptide, 7f
- POP, *see* prolyl oligopeptidase
- Prolyl endopeptidase
 - characteristics, 47, 93, 103ff
 - expression, recombinant, 104f
 - cleavage of humanin, 103ff
 - purification, 103ff
- Prolyl oligopeptidase, 45, 93ff
- PYY, *see* peptide YY
- RANTES, *see* regulated on activation, normal T cell expressed and secreted
- Regulated on activation, normal T cell expressed and secreted, 4, 9f, 175, 224
- SDF-1, *see* stromal-cell-derived factor-1
- Sebocyte, 163ff
- stromal-cell-derived factor-1, 11f
- Substance P, 5, 13
- T2DM, *see* diabetes mellitus type 2
- TGF- β 1
 - expression in monocytes, 87ff
 - expression in T cells, 143ff, 179ff, 189ff
 - immunosuppression by, 143ff, 177ff
- UAMC00039
 - pharmacology, 73ff
 - structure, 74
 - toxicology profiling, 76ff
- Vasoactive intestinal peptide, 7
- VIP, *see* vasoactive intestinal peptide